The Therapeutic Potential of PROTACs
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 4293
Special Issue Editor
Special Issue Information
Dear Colleagues,
Proteolysis-targeting chimeras (PROTACs) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. It has received extensive attention from both academia and industry, as it can potentially access previously inaccessible targets. Since the report of the concept of PROTACs using the ubiquitin–proteasome system to degrade target proteins, more and more PROTACs molecules targeting tumor-related proteins have been reported one after another, and many of these key molecules have also entered clinical trials. In the future, we also firmly believe that with the wider discovery of PROTACs target proteins and the expansion of the use of ubiquitin ligases, PROTACs will inevitably expand its model beyond oncology and bring disruptive change to drug discovery.
This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the PROTACs field, as well as to elucidate future directions. Topics include: PROTAC technology, targeted protein degradation, degrader and drug development.
Dr. Rui Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PROTAC technology
- inaccessible targets
- targeted protein degradation
- drug discovery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
